A phase 2/3 trial evaluates the efficacy and safety of neoadjuvant therapy with gemcitabine-oxaliplatin, lenvatinib, and ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of the PREDICT-DNA study in the Journal of Clinical Oncology. The article, "The ...

A prospective, multicenter phase 2 trial evaluated the safety of neoadjuvant radiation plus immunotherapy before radical cystectomy for bladder cancer.

Neoadjuvant chemoimmunotherapy may beat immunotherapy alone when it comes to pathologic response, but its impact on survival remains to be seen.

KEYNOTE-B15 compared perioperative enfortumab vedotin plus pembrolizumab against neoadjuvant cisplatin-based chemotherapy in cisplatin-eligible MIBC, using event-free survival as the primary endpoint.

Machine learning for tracking planned versus delivered dose in pancreas SBRT. This is an ASCO Meeting Abstract from the 2022 ASCO Gastrointestinal Cancers Symposium. This abstract does not include a ...

The study explores the neoadjuvant approach: administering the immunotherapy drug Keytruda (pembrolizumab) before a surgeon ever picks up a scalpel. Researchers observed dramatic tumor shrinkage and, ...

China: A neoadjuvant combination regimen comprising chemotherapy, targeted therapy, and immunotherapy has demonstrated significant clinical benefit in patients with resectable ...

AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been accepted and granted Priority Review in the US for the ...

For high-risk patients with prostate cancer, treatment with novel hormonal agents (NHAs) followed by surgery can reduce the risk of recurrent and progressive cancer, compared to initial treatment with ...